Other Events ·
Pulse Biosciences reports 86% of patients achieved primary endpoint in PRECISE-BTN thyroid nodule study
PLSEPulse Biosciences, Inc.
Pulse Biosciences announced interim six-month results from its PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules. Among 43 patients evaluated, 86% achieved the primary endpoint of at least 50% nodule volume reduction, with a median reduction of 72%. Quality of life scores improved by 78%, and 82% of patients reported full resolution of neck pressure symptoms. No serious adverse events were reported. The company expects to report data for all enrolled patients as follow-up continues.